Lv3
392 积分 2024-01-29 加入
NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate
1天前
待确认
Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
3天前
已完结
Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R
25天前
已完结
Unraveling the future: innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy
1个月前
已完结
Incorporating Selenium into Heterocycles and Natural Products─From Chemical Properties to Pharmacological Activities
3个月前
已完结
Development of PROTAC Degrader Drugs for Cancer
4个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
5个月前
已完结
Structural Insights into Small-Molecule KRAS Inhibitors for Targeting KRAS Mutant Cancers
6个月前
已完结
Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies
7个月前
已完结
What influences the activity of Degrader−Antibody conjugates (DACs)
7个月前
已完结
皖公网安备34019202002308
